Half-year report
· Development of novel cancer immunotherapy Clevegen[®] (bexmarilimab) continues in Phase I/II MATINS trial across 10 tumour types · IV interferon beta-1a, Traumakine[®], being investigated as potential COVID-19 treatment in two ongoing global trials with preparations for US trial underway · Successful €14 million placing in April strengthens Company’s balance sheet · Additional grants of €3.3 million and €4.6 million loans awarded to drive R&D and CMC programmesHalf-year report, 24 September 2020 at 9.00 AM (EEST) TURKU, FINLAND – Faron Pharmaceuticals Oy (AIM: FARN, First